Overexpression and activation of Axl receptor tyrosine kinase have been widely accepted to
promote cell proliferation, chemotherapy resistance, invasion, and metastasis in several …

Background Nivolumab plus ipilimumab improves overall survival and is associated with
less toxicity compared with sunitinib in the first-line setting of advanced renal-cell carcinoma …

Background The economic burden of renal cell carcinoma (RCC) had been reported to be
significant in a previous review published in 2011. Objective The objective of this study was …

Background: As conditional survival could provide more relevant prognostic information at
each follow-up time, the present study aimed to assess conditional overall survival (COS) …

Background Volume of operative cases may be an important factor associated with
improved survival for early-stage pancreatic cancer. Most high-volume pancreatic centers …

Background Screening for renal cell carcinoma (RCC) has been identified as a key research
priority; however, no randomised control trials have been performed. Value of information …

Background To compare the predictive value of the current AJCC stage grouping for renal
cell carcinoma (RCC) to our modifications. Patients and methods A total of 2120 patients …

Background Second-or third-line treatment options for metastatic renal cell carcinoma
(mRCC) have dramatically changed in the last few years. There are no criteria for the choice …

Background Cabozantinib was approved by the European Medicines Agency and the
Federal Drug Administration as an option for sorafenib-resistant advanced hepatocellular …

Background Since the approval of tyrosine kinase inhibitors, angiogenesis inhibitors and
immune checkpoint inhibitors, the treatment landscape for advanced renal cell carcinoma …